Article thumbnail

Risk of Bladder Cancer Among Diabetic Patients Treated With Pioglitazone: Interim report of a longitudinal cohort study

By James D. Lewis, Assiamira Ferrara, Tiffany Peng, Monique Hedderson, Warren B. Bilker, Charles P. Quesenberry, David J. Vaughn, Lisa Nessel, Joseph Selby and Brian L. Strom
Topics: Original Research
Publisher: American Diabetes Association
OAI identifier: oai:pubmedcentral.nih.gov:3064051
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles

Citations

  1. a PPAR gamma agonist: potent promoter of hydroxybutyl(butyl)nitrosamine-induced urinary bladder cancers.
  2. (2009). Actos (Pioglitazone Hydrochloride) Tablets: Full Prescribing Information.
  3. (2008). Cancer incidence among patients treated with antidiabetic pharmacotherapy.
  4. (2007). Cancer risks in thiazolidinedione users compared to other anti-diabetic agents. Pharmacoepidemiol Drug Saf
  5. Comparison of WHO/ISUP and WHO classification of noninvasive papillary urothelialneoplasmsforriskofprogression.
  6. Diabetes and cancer: a consensus report.
  7. Diabetes mellitus and risk of bladder cancer: a meta-analysis. Diabetologia 2006;49:
  8. (2000). DivisionofResearch,NorthernCalifornia, and Center for Health Research, Northwest Division.
  9. (2005). Effects of PPARgamma and combined agonists on the urinary tract of rats and other species. Toxicol Sci
  10. Emslie-Smith AM,AlessiDR,MorrisAD.Metforminand reducedriskofcancerindiabeticpatients.
  11. etal.Expressionofperoxisomeproliferatoractivated receptors (PPARs) in human urinary bladder carcinoma and growth inhibition by its agonists.
  12. (1999). Expression of peroxisome proliferator-activated receptor gamma (PPARgamma) in human transitional bladder cancer and its role in inducing cell death. Neoplasia
  13. (1998). Ligand for peroxisome proliferatoractivated receptor gamma (troglitazone) haspotentantitumoreffectagainsthuman prostate cancer both in vitro and in vivo.
  14. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells.
  15. (1998). Ligandsfor peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice.
  16. (2001). NakashiroKI,HayashiY,KitaA,etal.Role ofperoxisomeproliferator-activatedreceptor gammaanditsligandsinnon-neoplasticand neoplastic human urothelial cells.
  17. Papillary urothelial neoplasms of low malignant potential. Clinical and biologic implications.
  18. Rosiglitazone and risk of cancer: a meta-analysis of randomized clinical trials.
  19. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone ClinicalTrial In macroVascular Events): a randomised controlled trial.
  20. (2010). Surveillance Epidemiology and End Results Fast Stats.
  21. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor.
  22. (2011). The influence of glucose-lowering therapies on cancer risk in type 2 diabetes.
  23. (2007). Thiazolidinediones and the risk of lung, prostate, and colon cancer in patients with diabetes.
  24. (2011). Urothelial carcinogenesis in the urinary bladder of male rats treated with muraglitazar, a PPAR alpha/gamma agonist: evidence for urolithiasis as the care.diabetesjournals.org DIABETES CARE,